XML 62 R47.htm IDEA: XBRL DOCUMENT v3.19.1

License and Collaboration Agreements - Additional Information (Detail)							1 Months Ended				3 Months Ended											6 Months Ended		12 Months Ended
	Jan. 01, 2021	Jan. 01, 2020 USD ($)	Jan. 01, 2019 USD ($)	Jan. 01, 2019	Dec. 12, 2018	Jul. 10, 2017 USD ($)	Nov. 30, 2018 USD ($)	Oct. 25, 2016 USD ($)	Mar. 31, 2013 USD ($)	Jun. 30, 2011 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2018 USD ($) Country	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Collaborative Agreements And Contracts [Line Items]
Revenue											$ 2,442,000	$ 486,000	$ 715,000	$ 928,000	$ 933,000	$ 385,000	$ 701,000	$ 590,000	$ 5,971,000		$ 277,000	$ 2,928,000	$ 1,318,000	$ 2,961,000	$ 7,539,000	$ 1,620,000
Accounts receivable											627,000		353,000				251,000					627,000		353,000	251,000
Deferred revenue											15,000											15,000
Deferred Revenue, Current											30,000		0				50,000					30,000		0	50,000
Collaborative Research and Development [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																						$ 1,883,000	601,000	1,343,000	6,569,000	398,000
ILUVIEN [Member] | Europe [Member]
Collaborative Agreements And Contracts [Line Items]
Number of countries in which lead licensed product received regulatory approval | Country																						17
Royalty Income [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																						$ 1,045,000	$ 717,000	1,618,000	970,000	1,222,000
OncoSil Medical UK Limited [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of non-royalty consideration received from sublicense																						20.00%
Royalty percentage earned from sales of product																						8.00%
License agreement commencement date																						2012-12
Receipt of upfront license fee									$ 100,000
OncoSil Medical UK Limited [Member] | Collaborative Research and Development [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																						$ 100,000		$ 100,000	100,000	100,000
Prior Alimera Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of company's share of net profits																								20.00%
Pre-profitability net losses percentage																								20.00%
Maximum percentage offset of current period net profits against previously incurred and unapplied pre-profitability quarterly net losses																								4.00%
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses																								16.00%
Percentage of royalties received from sublicense																								20.00%
Percentage of non-royalty consideration received from sublicense																								33.00%
Total revenues earned																						$ 39,000		$ 148,000	659,000	233,000
Amount received, profit share from sale of licensed products																								50,000	585,000
Recognition of deferred revenue from arbitration settlement																									136,000
Non-royalty consideration received from sub license																										157,000
Amended Alimera Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product																						2.00%
Contingently recoverable accumulated commercialization losses						$ 25,000,000
Partial cancellation of contingently recoverable accumulated commercialization losses in lieu of upfront license fee						$ 10,000,000
Royalty percentage offset for amounts earned above 2% to be applied against balance of accumulated commercialization losses					50.00%
Proceeds received from earned sales-based royalties											218,000											$ 588,000		575,000
Amended Alimera Agreement [Member] | Scenario, Forecast [Member]
Collaborative Agreements And Contracts [Line Items]
Calendar year net sales threshold for increase in royalty rate			$ 75,000,000
Royalty percentage offset for amounts earned above 2% to be applied against balance of accumulated commercialization losses	20.00%			50.00%
Additional cancellation of contingently recoverable commercialization losses		$ 5,000,000
Amended Alimera Agreement [Member] | Scenario, Forecast [Member] | Minimum [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product			6.00%
Amended Alimera Agreement [Member] | Scenario, Forecast [Member] | Maximum [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product			8.00%
Bausch and Lomb [Member]
Collaborative Agreements And Contracts [Line Items]
Accounts receivable											253,000		$ 306,000				$ 246,000					253,000		306,000	246,000
Bausch and Lomb [Member] | Royalty Income [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																						456,000		1,000,000	970,000	1,200,000
Feasibility Study Agreement [Member] | Collaborative Research and Development [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																								$ 1,100,000	$ 211,000	$ 33,000
Pfizer Collaboration Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Option period to acquire license								60 days
Upfront Cash Payment Received Under Collaboration Agreement										$ 2,300,000
Estimated selling price of the deliverables for revenue recognition										$ 6,700,000
License Option Exercise Upfront Payment								$ 10,000,000
Pfizer Collaboration Agreement [Member] | Collaborative Research and Development [Member]
Collaborative Agreements And Contracts [Line Items]
Revenue																				$ 5,600,000
Ocumension Therapeutics [Member]
Collaborative Agreements And Contracts [Line Items]
Total revenues earned											1,700,000
Receipt of upfront license fee							$ 1,750,000
Deferred Revenue, Current											$ 30,000											$ 30,000
Potential future payments that could be due based on achievement by Ocumension of certain prescribed development, regulatory and commercial sales-based milestones events							$ 10,000,000

X

- Definition

Additional cancellation of contingently recoverable commercialization losses.

+ References

No definition available.

+ Details

Name:	eypt_AdditionalCancellationOfContingentlyRecoverableCommercializationLosses
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Calendar year net sales threshold for increase in royalty rate.

+ References

No definition available.

+ Details

Name:	eypt_CalendarYearNetSalesThresholdForIncreaseInRoyaltyRate
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Cancellation of contingently recoverable accumulated commercialization losses.

+ References

No definition available.

+ Details

Name:	eypt_CancellationOfContingentlyRecoverableAccumulatedCommercializationLosses
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Agreements And Contracts [Line Items]

+ References

No definition available.

+ Details

Name:	eypt_CollaborativeAgreementsAndContractsLineItems
Namespace Prefix:	eypt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative research and development revenue.

+ References

No definition available.

+ Details

Name:	eypt_CollaborativeResearchAndDevelopmentRevenue
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Contingently recoverable accumulated commercialization losses.

+ References

No definition available.

+ Details

Name:	eypt_ContingentlyRecoverableAccumulatedCommercializationLosses
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

License Agreement Start Year Month

+ References

No definition available.

+ Details

Name:	eypt_LicenseAgreementStartYearMonth
Namespace Prefix:	eypt_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License Option Exercise Upfront Payment

+ References

No definition available.

+ Details

Name:	eypt_LicenseOptionExerciseUpfrontPayment
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum percentage of quarterly profit sharing offset by previously incurred and unapplied pre profitability net losses.

+ References

No definition available.

+ Details

Name:	eypt_MaximumPercentageOfQuarterlyProfitSharingOffsetByPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Non royalty consideration earned.

+ References

No definition available.

+ Details

Name:	eypt_NonRoyaltyConsiderationEarned
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non royalty consideration percentage.

+ References

No definition available.

+ Details

Name:	eypt_NonRoyaltyConsiderationPercentage
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of countries in which lead licensed product received regulatory approval.

+ References

No definition available.

+ Details

Name:	eypt_NumberOfCountriesInWhichLeadLicensedProductReceivedRegulatoryApproval
Namespace Prefix:	eypt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Option period to acquire license.

+ References

No definition available.

+ Details

Name:	eypt_OptionPeriodToAcquireLicense
Namespace Prefix:	eypt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty offsetting.

+ References

No definition available.

+ Details

Name:	eypt_PercentageOfRoyaltyOffsetting
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of potential future payments to be received upon the achievement of prescribed licensee milestone events.

+ References

No definition available.

+ Details

Name:	eypt_PotentialFuturePaymentsToBeReceivedUponTheAchievementOfPrescribedLicenseeMilestoneEvents
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Proceeds from earned profit share and collaborative research and development revenue.

+ References

No definition available.

+ Details

Name:	eypt_ProceedsFromEarnedProfitShareAndCollaborativeResearchAndDevelopmentRevenue
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Proceeds received from earned sales-based royalties.

+ References

No definition available.

+ Details

Name:	eypt_ProceedsReceivedFromEarnedSalesbasedRoyalties
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Profit Sharing on Sale of Product Minimum Percentage After Maximum Allowable Offset of Previously Incurred and Unapplied Pre Profitability Net Losses.

+ References

No definition available.

+ Details

Name:	eypt_ProfitSharingOnSaleOfProductMinimumPercentageAfterMaximumAllowableOffsetOfPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Profit sharing on sale of product percentage.

+ References

No definition available.

+ Details

Name:	eypt_ProfitSharingOnSaleOfProductPercentage
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Recognition of previously deferred revenue.

+ References

No definition available.

+ Details

Name:	eypt_RecognitionOfPreviouslyDeferredRevenue
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Royalty percentage earned from sales of product

+ References

No definition available.

+ Details

Name:	eypt_RoyaltyPercentageEarnedFromProductSales
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Rate Percentage

+ References

No definition available.

+ Details

Name:	eypt_RoyaltyRatePercentage
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Share percentage of pre-profitability net losses on sale of product.

+ References

No definition available.

+ Details

Name:	eypt_SharePercentageOfPreProfitabilityNetLossesOnSaleOfProduct
Namespace Prefix:	eypt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront Cash Payment Received Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	eypt_UpfrontCashPaymentReceivedUnderCollaborationAgreement
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront cash payment received under license agreement.

+ References

No definition available.

+ Details

Name:	eypt_UpfrontLicenseFeeReceived
Namespace Prefix:	eypt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=eypt_ILUVIENMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_OncoSilMedicalUKLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_PriorAlimeraAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_AmendedAlimeraAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_BauschAndLombMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_FeasibilityStudyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_PfizerCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: